Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM.

Clin Cancer Res. 2002 Dec;8(12):3702-9.

2.

Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR.

Invest New Drugs. 2002 Feb;20(1):83-93.

PMID:
12003197
3.

Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.

Schrijvers D, Bos AM, Dyck J, de Vries EG, Wanders J, Roelvink M, Fumoleau P, Bortini S, Vermorken JB.

Ann Oncol. 2002 Mar;13(3):385-91.

PMID:
11996468
4.

Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.

Bos AM, de Vries EG, Dombernovsky P, Aamdal S, Uges DR, Schrijvers D, Wanders J, Roelvink MW, Hanauske AR, Bortini S, Capriati A, Crea AE, Vermorken JB.

Cancer Chemother Pharmacol. 2001 Nov;48(5):361-9.

PMID:
11761453
5.

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.

Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, Smyth JF, Morant R, de Vries MJ, Roelvink M, Fumoleau P; European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2001 Nov;37(17):2194-8.

PMID:
11677106
6.

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.

Gamucci T, Paridaens R, Heinrich B, Schellens JH, Pavlidis N, Verweij J, Sessa C, Kaye S, Roelvink M, Wanders J, Hanauske A.

Ann Oncol. 2000 Jul;11(7):793-7.

PMID:
10997805
7.

Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG).

Sessa C, Wanders J, Roelvink M, Dombernowsky P, Nielsen D, Morant R, Drings P, Wissel P, Hanauske AR.

Ann Oncol. 2000 Feb;11(2):207-10.

PMID:
10761757
8.

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.

Judson I, Cerny T, Epelbaum R, Dunlop D, Smyth J, Schaefer B, Roelvink M, Kaplan S, Hanauske A.

Ann Oncol. 1997 Jun;8(6):604-6.

PMID:
9261531
9.

Analgesic and spasmolytic effects of dipyrone, hyoscine-N-butylbromide and a combination of the two in ponies.

Roelvink ME, Goossens L, Kalsbeek HC, Wensing T.

Vet Rec. 1991 Oct 26;129(17):378-80.

PMID:
1746114
10.

Aujeszky's disease in horses fulfils Koch's postulates.

Kimman TG, Binkhorst GJ, van den Ingh TS, Pol JM, Gielkens AL, Roelvink ME.

Vet Rec. 1991 Feb 2;128(5):103-6.

PMID:
1850887

Supplemental Content

Loading ...
Support Center